ID   PTN14_HUMAN             Reviewed;        1187 AA.
AC   Q15678; Q5VSI0;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   14-OCT-2008, sequence version 2.
DT   28-JUN-2023, entry version 204.
DE   RecName: Full=Tyrosine-protein phosphatase non-receptor type 14;
DE            EC=3.1.3.48;
DE   AltName: Full=Protein-tyrosine phosphatase pez;
GN   Name=PTPN14; Synonyms=PEZ, PTPD2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Mammary carcinoma;
RX   PubMed=7733990; DOI=10.1006/bbrc.1995.1591;
RA   Smith A.L., Mitchell P.J., Shipley J., Gusterson B.A., Rogers M.V.,
RA   Crompton M.R.;
RT   "Pez: a novel human cDNA encoding protein tyrosine phosphatase- and ezrin-
RT   like domains.";
RL   Biochem. Biophys. Res. Commun. 209:959-965(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Heart, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=10934049; DOI=10.1242/jcs.113.17.3117;
RA   Wadham C., Gamble J.R., Vadas M.A., Khew-Goodall Y.;
RT   "Translocation of protein tyrosine phosphatase Pez/PTPD2/PTP36 to the
RT   nucleus is associated with induction of cell proliferation.";
RL   J. Cell Sci. 113:3117-3123(2000).
RN   [6]
RP   FUNCTION.
RX   PubMed=12808048; DOI=10.1091/mbc.e02-09-0577;
RA   Wadham C., Gamble J.R., Vadas M.A., Khew-Goodall Y.;
RT   "The protein tyrosine phosphatase Pez is a major phosphatase of adherens
RT   junctions and dephosphorylates beta-catenin.";
RL   Mol. Biol. Cell 14:2520-2529(2003).
RN   [7]
RP   FUNCTION.
RX   PubMed=17893246; DOI=10.1083/jcb.200705035;
RA   Wyatt L., Wadham C., Crocker L.A., Lardelli M., Khew-Goodall Y.;
RT   "The protein tyrosine phosphatase Pez regulates TGFbeta, epithelial-
RT   mesenchymal transition, and organ development.";
RL   J. Cell Biol. 178:1223-1235(2007).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-486, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [11]
RP   FUNCTION, INTERACTION WITH FLT4, AND INVOLVEMENT IN CATLPH.
RX   PubMed=20826270; DOI=10.1016/j.ajhg.2010.08.008;
RA   Au A.C., Hernandez P.A., Lieber E., Nadroo A.M., Shen Y.M., Kelley K.A.,
RA   Gelb B.D., Diaz G.A.;
RT   "Protein tyrosine phosphatase PTPN14 is a regulator of lymphatic function
RT   and choanal development in humans.";
RL   Am. J. Hum. Genet. 87:436-444(2010).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-591; SER-594 AND SER-642, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [13]
RP   SUBCELLULAR LOCATION, INDUCTION, FUNCTION, INTERACTION WITH YAP1; CUL2 AND
RP   LRR1, AND UBIQUITINATION.
RX   PubMed=22948661; DOI=10.1101/gad.192955.112;
RA   Wang W., Huang J., Wang X., Yuan J., Li X., Feng L., Park J.I., Chen J.;
RT   "PTPN14 is required for the density-dependent control of YAP1.";
RL   Genes Dev. 26:1959-1971(2012).
RN   [14]
RP   INVOLVEMENT IN HTT, AND FUNCTION.
RX   PubMed=22233626; DOI=10.1038/ncomms1633;
RA   Benzinou M., Clermont F.F., Letteboer T.G., Kim J.H., Espejel S.,
RA   Harradine K.A., Arbelaez J., Luu M.T., Roy R., Quigley D., Higgins M.N.,
RA   Zaid M., Aouizerat B.E., van Amstel J.K., Giraud S., Dupuis-Girod S.,
RA   Lesca G., Plauchu H., Hughes C.C., Westermann C.J., Akhurst R.J.;
RT   "Mouse and human strategies identify PTPN14 as a modifier of angiogenesis
RT   and hereditary haemorrhagic telangiectasia.";
RL   Nat. Commun. 3:616-616(2012).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-594, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   INTERACTION WITH YAP1, FUNCTION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22525271; DOI=10.1038/onc.2012.147;
RA   Liu X., Yang N., Figel S.A., Wilson K.E., Morrison C.D., Gelman I.H.,
RA   Zhang J.;
RT   "PTPN14 interacts with and negatively regulates the oncogenic function of
RT   YAP.";
RL   Oncogene 32:1266-1273(2013).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 886-1187.
RX   PubMed=16534812; DOI=10.1002/prot.20958;
RA   Barr A.J., Debreczeni J.E., Eswaran J., Knapp S.;
RT   "Crystal structure of human protein tyrosine phosphatase 14 (PTPN14) at
RT   1.65-A resolution.";
RL   Proteins 63:1132-1136(2006).
RN   [18]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLU-159 AND PRO-360.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Protein tyrosine phosphatase which may play a role in the
CC       regulation of lymphangiogenesis, cell-cell adhesion, cell-matrix
CC       adhesion, cell migration, cell growth and also regulates TGF-beta gene
CC       expression, thereby modulating epithelial-mesenchymal transition.
CC       Mediates beta-catenin dephosphorylation at adhesion junctions. Acts as
CC       a negative regulator of the oncogenic property of YAP, a downstream
CC       target of the hippo pathway, in a cell density-dependent manner. May
CC       function as a tumor suppressor. {ECO:0000269|PubMed:10934049,
CC       ECO:0000269|PubMed:12808048, ECO:0000269|PubMed:17893246,
CC       ECO:0000269|PubMed:20826270, ECO:0000269|PubMed:22233626,
CC       ECO:0000269|PubMed:22525271, ECO:0000269|PubMed:22948661}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + O-phospho-L-tyrosyl-[protein] = L-tyrosyl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:10684, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620; EC=3.1.3.48; Evidence={ECO:0000255|PROSITE-
CC         ProRule:PRU10044};
CC   -!- SUBUNIT: Interacts with FLT4; the interaction is enhanced by
CC       stimulation with VEGFC. Interacts (via PPxY motifs) with YAP1 (via WW
CC       domains); this interaction leads to the cytoplasmic sequestration of
CC       YAP1 and inhibits its transcriptional co-activator activity.
CC       {ECO:0000269|PubMed:20826270, ECO:0000269|PubMed:22525271,
CC       ECO:0000269|PubMed:22948661}.
CC   -!- INTERACTION:
CC       Q15678; A2BDD9: AMOT; NbExp=3; IntAct=EBI-1237156, EBI-17286414;
CC       Q15678; Q15654: TRIP6; NbExp=3; IntAct=EBI-1237156, EBI-742327;
CC       Q15678; P46937: YAP1; NbExp=7; IntAct=EBI-1237156, EBI-1044059;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cytoplasm, cytoskeleton {ECO:0000250}.
CC       Nucleus. Note=Translocation into the nucleus is associated with
CC       induction of cell proliferation. Partially colocalized with actin
CC       filaments at the plasma membrane.
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- INDUCTION: Up-regulated at protein level by cell density. However, at
CC       the mRNA level remains the same regardless of the status of cell
CC       density. {ECO:0000269|PubMed:22948661}.
CC   -!- PTM: Ubiquitinated by the ECS (Elongin BC-CUL2/5-SOCS-box protein)/LRR1
CC       E3 ligase complex and subsequently targeted to proteasomal degradation.
CC       {ECO:0000269|PubMed:22948661}.
CC   -!- DISEASE: Choanal atresia and lymphedema (CATLPH) [MIM:613611]: A
CC       disease characterized by posterior choanal atresia and lymphedema.
CC       Additional features are a high-arched palate, hypoplastic nipples, and
CC       mild pectus excavatum. {ECO:0000269|PubMed:20826270}. Note=The disease
CC       is caused by variants affecting the gene represented in this entry. A
CC       homozygous deletion in PTPN14 predicted to result in frameshift and
CC       premature truncation, has been shown to be the cause of choanal atresia
CC       and lymphedema in one family.
CC   -!- DISEASE: Note=Influence clinical severity of hereditary haemorragic
CC       telagiectasia (HHT). {ECO:0000269|PubMed:22233626}.
CC   -!- SIMILARITY: Belongs to the protein-tyrosine phosphatase family. Non-
CC       receptor class subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/41913/PTPN14";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X82676; CAA57993.1; -; mRNA.
DR   EMBL; AL929236; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL603838; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL445305; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL592216; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471100; EAW93351.1; -; Genomic_DNA.
DR   EMBL; BC101754; AAI01755.1; -; mRNA.
DR   EMBL; BC104803; AAI04804.1; -; mRNA.
DR   CCDS; CCDS1514.1; -.
DR   PIR; JC4155; JC4155.
DR   RefSeq; NP_005392.2; NM_005401.4.
DR   RefSeq; XP_016857430.1; XM_017001941.1.
DR   PDB; 2BZL; X-ray; 1.65 A; A=886-1187.
DR   PDB; 6IWD; X-ray; 1.80 A; A=886-1187.
DR   PDB; 6JJW; X-ray; 2.40 A; U=428-455.
DR   PDBsum; 2BZL; -.
DR   PDBsum; 6IWD; -.
DR   PDBsum; 6JJW; -.
DR   AlphaFoldDB; Q15678; -.
DR   SMR; Q15678; -.
DR   BioGRID; 111748; 158.
DR   DIP; DIP-38131N; -.
DR   IntAct; Q15678; 35.
DR   MINT; Q15678; -.
DR   STRING; 9606.ENSP00000355923; -.
DR   BindingDB; Q15678; -.
DR   ChEMBL; CHEMBL3317332; -.
DR   DEPOD; PTPN14; -.
DR   iPTMnet; Q15678; -.
DR   PhosphoSitePlus; Q15678; -.
DR   BioMuta; PTPN14; -.
DR   DMDM; 209572662; -.
DR   EPD; Q15678; -.
DR   jPOST; Q15678; -.
DR   MassIVE; Q15678; -.
DR   MaxQB; Q15678; -.
DR   PaxDb; Q15678; -.
DR   PeptideAtlas; Q15678; -.
DR   ProteomicsDB; 60701; -.
DR   Antibodypedia; 34618; 190 antibodies from 28 providers.
DR   DNASU; 5784; -.
DR   Ensembl; ENST00000366956.10; ENSP00000355923.4; ENSG00000152104.12.
DR   GeneID; 5784; -.
DR   KEGG; hsa:5784; -.
DR   MANE-Select; ENST00000366956.10; ENSP00000355923.4; NM_005401.5; NP_005392.2.
DR   UCSC; uc001hkk.3; human.
DR   AGR; HGNC:9647; -.
DR   CTD; 5784; -.
DR   DisGeNET; 5784; -.
DR   GeneCards; PTPN14; -.
DR   HGNC; HGNC:9647; PTPN14.
DR   HPA; ENSG00000152104; Low tissue specificity.
DR   MalaCards; PTPN14; -.
DR   MIM; 603155; gene.
DR   MIM; 613611; phenotype.
DR   neXtProt; NX_Q15678; -.
DR   OpenTargets; ENSG00000152104; -.
DR   Orphanet; 99141; Lymphedema-posterior choanal atresia syndrome.
DR   PharmGKB; PA33989; -.
DR   VEuPathDB; HostDB:ENSG00000152104; -.
DR   eggNOG; KOG0792; Eukaryota.
DR   GeneTree; ENSGT00940000156874; -.
DR   HOGENOM; CLU_006456_1_0_1; -.
DR   InParanoid; Q15678; -.
DR   OMA; FKKCRQY; -.
DR   OrthoDB; 3108587at2759; -.
DR   PhylomeDB; Q15678; -.
DR   TreeFam; TF315900; -.
DR   BRENDA; 3.1.3.48; 2681.
DR   PathwayCommons; Q15678; -.
DR   Reactome; R-HSA-9008059; Interleukin-37 signaling.
DR   SignaLink; Q15678; -.
DR   SIGNOR; Q15678; -.
DR   BioGRID-ORCS; 5784; 34 hits in 1176 CRISPR screens.
DR   ChiTaRS; PTPN14; human.
DR   EvolutionaryTrace; Q15678; -.
DR   GeneWiki; PTPN14; -.
DR   GenomeRNAi; 5784; -.
DR   Pharos; Q15678; Tbio.
DR   PRO; PR:Q15678; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q15678; protein.
DR   Bgee; ENSG00000152104; Expressed in buccal mucosa cell and 181 other tissues.
DR   ExpressionAtlas; Q15678; baseline and differential.
DR   Genevisible; Q15678; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IMP:UniProtKB.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:UniProtKB.
DR   GO; GO:0003712; F:transcription coregulator activity; IMP:UniProtKB.
DR   GO; GO:0001946; P:lymphangiogenesis; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0006470; P:protein dephosphorylation; TAS:ProtInc.
DR   GO; GO:0046825; P:regulation of protein export from nucleus; IDA:UniProtKB.
DR   CDD; cd14473; FERM_B-lobe; 1.
DR   CDD; cd13188; FERM_C_PTPN14_PTPN21; 1.
DR   CDD; cd17191; FERM_F1_PTPN14; 1.
DR   CDD; cd14599; PTPc-N14; 1.
DR   Gene3D; 1.20.80.10; -; 1.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1.
DR   Gene3D; 3.90.190.10; Protein tyrosine phosphatase superfamily; 1.
DR   IDEAL; IID00476; -.
DR   InterPro; IPR019749; Band_41_domain.
DR   InterPro; IPR014352; FERM/acyl-CoA-bd_prot_sf.
DR   InterPro; IPR035963; FERM_2.
DR   InterPro; IPR019748; FERM_central.
DR   InterPro; IPR019747; FERM_CS.
DR   InterPro; IPR000299; FERM_domain.
DR   InterPro; IPR018979; FERM_N.
DR   InterPro; IPR018980; FERM_PH-like_C.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR000242; PTP_cat.
DR   InterPro; IPR014392; PTP_non-rcpt_14/21.
DR   InterPro; IPR041782; PTPN14/21_FERM_C.
DR   InterPro; IPR016130; Tyr_Pase_AS.
DR   InterPro; IPR003595; Tyr_Pase_cat.
DR   InterPro; IPR000387; Tyr_Pase_dom.
DR   InterPro; IPR029071; Ubiquitin-like_domsf.
DR   PANTHER; PTHR45706; TYROSINE-PROTEIN PHOSPHATASE; 1.
DR   PANTHER; PTHR45706:SF6; TYROSINE-PROTEIN PHOSPHATASE NON-RECEPTOR TYPE 14; 1.
DR   Pfam; PF09380; FERM_C; 1.
DR   Pfam; PF00373; FERM_M; 1.
DR   Pfam; PF09379; FERM_N; 1.
DR   Pfam; PF00102; Y_phosphatase; 1.
DR   PIRSF; PIRSF000934; Tyr-Ptase_nr14; 1.
DR   PRINTS; PR00935; BAND41.
DR   PRINTS; PR00700; PRTYPHPHTASE.
DR   SMART; SM00295; B41; 1.
DR   SMART; SM01196; FERM_C; 1.
DR   SMART; SM00194; PTPc; 1.
DR   SMART; SM00404; PTPc_motif; 1.
DR   SUPFAM; SSF52799; (Phosphotyrosine protein) phosphatases II; 1.
DR   SUPFAM; SSF50729; PH domain-like; 1.
DR   SUPFAM; SSF47031; Second domain of FERM; 1.
DR   SUPFAM; SSF54236; Ubiquitin-like; 1.
DR   PROSITE; PS00660; FERM_1; 1.
DR   PROSITE; PS00661; FERM_2; 1.
DR   PROSITE; PS50057; FERM_3; 1.
DR   PROSITE; PS00383; TYR_PHOSPHATASE_1; 1.
DR   PROSITE; PS50056; TYR_PHOSPHATASE_2; 1.
DR   PROSITE; PS50055; TYR_PHOSPHATASE_PTP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cytoplasm; Cytoskeleton; Hydrolase; Nucleus; Phosphoprotein;
KW   Protein phosphatase; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN           1..1187
FT                   /note="Tyrosine-protein phosphatase non-receptor type 14"
FT                   /id="PRO_0000219437"
FT   DOMAIN          21..306
FT                   /note="FERM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00084"
FT   DOMAIN          909..1180
FT                   /note="Tyrosine-protein phosphatase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00160"
FT   REGION          510..531
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          671..690
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          787..824
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        1121
FT                   /note="Phosphocysteine intermediate"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00160,
FT                   ECO:0000255|PROSITE-ProRule:PRU10044"
FT   BINDING         1079
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         1121..1127
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         1165
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         314
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62130"
FT   MOD_RES         461
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62130"
FT   MOD_RES         486
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17525332"
FT   MOD_RES         591
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         593
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62130"
FT   MOD_RES         594
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         642
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         831
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62130"
FT   VARIANT         159
FT                   /note="Q -> E (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035849"
FT   VARIANT         360
FT                   /note="H -> P (in a breast cancer sample; somatic mutation;
FT                   dbSNP:rs112523432)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035850"
FT   VARIANT         505
FT                   /note="V -> F (in dbSNP:rs12239356)"
FT                   /id="VAR_046995"
FT   CONFLICT        392
FT                   /note="H -> D (in Ref. 1; CAA57993)"
FT                   /evidence="ECO:0000305"
FT   HELIX           445..451
FT                   /evidence="ECO:0007829|PDB:6JJW"
FT   HELIX           896..903
FT                   /evidence="ECO:0007829|PDB:2BZL"
FT   HELIX           909..914
FT                   /evidence="ECO:0007829|PDB:2BZL"
FT   TURN            926..929
FT                   /evidence="ECO:0007829|PDB:2BZL"
FT   HELIX           931..933
FT                   /evidence="ECO:0007829|PDB:2BZL"
FT   HELIX           946..948
FT                   /evidence="ECO:0007829|PDB:2BZL"
FT   STRAND          949..951
FT                   /evidence="ECO:0007829|PDB:6IWD"
FT   STRAND          956..958
FT                   /evidence="ECO:0007829|PDB:6IWD"
FT   STRAND          964..972
FT                   /evidence="ECO:0007829|PDB:2BZL"
FT   STRAND          975..982
FT                   /evidence="ECO:0007829|PDB:2BZL"
FT   TURN            987..989
FT                   /evidence="ECO:0007829|PDB:2BZL"
FT   HELIX           990..999
FT                   /evidence="ECO:0007829|PDB:2BZL"
FT   STRAND          1004..1007
FT                   /evidence="ECO:0007829|PDB:2BZL"
FT   STRAND          1011..1013
FT                   /evidence="ECO:0007829|PDB:2BZL"
FT   TURN            1029..1031
FT                   /evidence="ECO:0007829|PDB:6IWD"
FT   STRAND          1032..1035
FT                   /evidence="ECO:0007829|PDB:2BZL"
FT   STRAND          1038..1047
FT                   /evidence="ECO:0007829|PDB:2BZL"
FT   STRAND          1049..1060
FT                   /evidence="ECO:0007829|PDB:2BZL"
FT   TURN            1061..1063
FT                   /evidence="ECO:0007829|PDB:2BZL"
FT   STRAND          1066..1074
FT                   /evidence="ECO:0007829|PDB:2BZL"
FT   STRAND          1079..1081
FT                   /evidence="ECO:0007829|PDB:2BZL"
FT   HELIX           1086..1103
FT                   /evidence="ECO:0007829|PDB:2BZL"
FT   HELIX           1105..1107
FT                   /evidence="ECO:0007829|PDB:2BZL"
FT   STRAND          1117..1125
FT                   /evidence="ECO:0007829|PDB:2BZL"
FT   HELIX           1126..1142
FT                   /evidence="ECO:0007829|PDB:2BZL"
FT   HELIX           1149..1157
FT                   /evidence="ECO:0007829|PDB:2BZL"
FT   HELIX           1167..1183
FT                   /evidence="ECO:0007829|PDB:2BZL"
SQ   SEQUENCE   1187 AA;  135261 MW;  1D22F1C8ED06C096 CRC64;
     MPFGLKLRRT RRYNVLSKNC FVTRIRLLDS NVIECTLSVE STGQECLEAV AQRLELRETH
     YFGLWFLSKS QQARWVELEK PLKKHLDKFA NEPLLFFGVM FYVPNVSWLQ QEATRYQYYL
     QVKKDVLEGR LRCTLDQVIR LAGLAVQADF GDYNQFDSQD FLREYVLFPM DLALEEAVLE
     ELTQKVAQEH KAHSGILPAE AELMYINEVE RLDGFGQEIF PVKDNHGNCV HLGIFFMGIF
     VRNRIGRQAV IYRWNDMGNI THNKSTILVE LINKEETALF HTDDIENAKY ISRLFATRHK
     FYKQNKICTE QSNSPPPIRR QPTWSRSSLP RQQPYILPPV HVQCGEHYSE THTSQDSIFH
     GNEEALYCNS HNSLDLNYLN GTVTNGSVCS VHSVNSLNCS QSFIQASPVS SNLSIPGSDI
     MRADYIPSHR HSAIIVPSYR PTPDYETVMR QMKRGILHTD SQSQSLRNLN IINTHAYNQP
     EDLVYSQPEM RERHPYTVPY GPQGVYSNKL VSPSDQRNPK NNVVPSKPGA SAISHTVSTP
     ELANMQLQGS HNYSTAHMLK NYLFRPPPPY PRPRPATSTP DLASHRHKYV SGSSPDLVTR
     KVQLSVKTFQ EDSSPVVHQS LQEVSEPLTA TKHHGTVNKR HSLEVMNSMV RGMEAMTLKS
     LHLPMARRNT LREQGPPEEG SGSHEVPQLP QYHHKKTFSD ATMLIHSSES EEEEEEAPES
     VPQIPMLREK MEYSAQLQAA LARIPNKPPP EYPGPRKSVS NGALRQDQAS LPPAMARARV
     LRHGPAKAIS MSRTDPPAVN GASLGPSISE PDLTSVKERV KKEPVKERPV SEMFSLEDSI
     IEREMMIRNL EKQKMAGLEA QKRPLMLAAL NGLSVARVSG REENRVDATR VPMDERFRTL
     KKKLEEGMVF TEYEQIPKKK ANGIFSTAAL PENAERSRIR EVVPYEENRV ELIPTKENNT
     GYINASHIKV VVGGAEWHYI ATQGPLPHTC HDFWQMVWEQ GVNVIAMVTA EEEGGRTKSH
     RYWPKLGSKH SSATYGKFKV TTKFRTDSVC YATTGLKVKH LLSGQERTVW HLQYTDWPDH
     GCPEDVQGFL SYLEEIQSVR RHTNSMLEGT KNRHPPIVVH CSAGVGRTGV LILSELMIYC
     LEHNEKVEVP MMLRLLREQR MFMIQTIAQY KFVYQVLIQF LQNSRLI
//
